SCHEMBL30912173

CC[C@H](C)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC

nearest known ligand 0.54

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	7/20	0.52

▸	OPRM1	P35372	2/20	0.50

▸	OPRD1	P41143	2/20	0.50

▸	OPRK1	P41145	1/20	0.50

▸	ECE1	P42892	1/20	0.49

▸	MUS81	Q96NY9	1/20	0.49

▸	APC	P25054	1/20	0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30912174	0.91	GLP1R (0.64)	GLP1ROPRD1ECE1MUS81
SCHEMBL29960036	0.90	OPRD1 (0.55)	OPRM1OPRD1OPRK1
SCHEMBL31038686	0.88	OPRD1 (0.58)	GLP1ROPRM1OPRD1OPRK1ECE1
SCHEMBL31098023	0.88	OPRD1 (0.60)	GLP1ROPRM1OPRD1OPRK1ECE1
SCHEMBL30719899	0.87	TFPI (0.63)	GLP1RECE1MUS81
SCHEMBL31672201	0.86	OPRM1 (0.56)	GLP1ROPRM1OPRD1OPRK1ECE1
SCHEMBL31257057	0.86	OPRD1 (0.58)	OPRM1OPRD1OPRK1APC
SCHEMBL31683365	0.86	BACE1 (0.56)	GLP1ROPRM1OPRD1OPRK1ECE1
SCHEMBL31256964	0.85	OPRD1 (0.58)	OPRM1OPRD1OPRK1
SCHEMBL30376274	0.84	OPRD1 (0.54)	GLP1ROPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
CN-112969711-B	Desensitization and improvement of kidney transplantation in HLA sensitized patients using cladagumab	西达赛奈医疗中心	2024-12-17	—	—	CN	disclosed
CN-113194996-B	Clazazumab for the treatment of chronic antibody-mediated organ transplant rejection	西达赛奈医疗中心	2024-06-28	—	—	CN	disclosed